FEB 27, 2017 10:11 AM PST

Durability of "Immune Checkpoint" Proves Vital for Antiviral Response

WRITTEN BY: Kara Marker

Thanks to the innate immune response, humans have an immediately-acting defense mechanism set in place against invading pathogens. The innate response is nonspecific; it employs the same tools to target a wide variety of incoming pathogens.

However, a careful balance must be kept between a too-strong and too-weak response; too weak and the pathogen is one step closer to invading the body. Too strong, and the immune response could do more harm than good, potentially even resulting in autoimmune disease.

A human epithelial cell infected with H3N1 influenza A virus (in green). Red, LC3 (cytosolic protein); blue, DNA. Imaged by super-resolution structured illumination microscopy. 50 Z-stacked images. Credit: Maria T. Sanchez, Mount Sinai School of Medicine

The role of a protein called K-homology splicing regulatory protein (KHSRP) is to inhibit the innate immune response to prevent a too-strong response, and it achieves this goal by binding to another innate immune protein called retinoic acid-inducible gene I (RIG-I). However, KHSRP and RIG-I interaction can backfire, weakening the immune response to viral RNA.

"RIG-I normally recognizes RNA molecules that arise during viral infections, but it can also mistakenly sense RNA present in normal cells,” explained senior author Sumit Chanda, PhD, from the Sanford Burnham Prebys Medical Discovery Institute. “Without KHSRP, the innate immune response could be erroneously turned on when there's no virus.”

RIG-1 receptors prompt the innate immune system to target viral RNA in the cell’s cytoplasm, triggering the innate antiviral process. This protein also turns on signaling that ultimately leads to the production of interferon, chemical messengers that initiate a domino effect of antiviral responses including the communication of a “warning” signal to nearby cells. Additionally, RIG-1 initiates the adaptive immune response, the second tier of immunity that coordinates specific attacks depending on the type of pathogen involved in the infection.

Chanda’s study involved sifting through libraries of human proteins to find the one that interacted with RIG-I to set the innate immune response in motion. "We found about 240 proteins, but we focused on KHSRP because it was the only one of the 240 that was found to inhibit the very early steps of RIG-I signaling,” explained Stephen Soonthornvacharin, PhD.

“Depleting KHSRP improved immune signaling and reduced viral replication in cell culture and in vivo, suggesting that drugs inhibiting the protein may have therapeutic value,” Chanda explained. Inhibiting KHSRP could be useful when developing antiviral drugs, anticancer therapies, and autoimmune disease treatments.

“Among the 240 RIG-I regulators we identified, 125 appear to activate RIG-I, so finding drugs that inhibit these proteins may be a way to treat autoimmune conditions involving too much interferon, like type 1 diabetes or lupus,” Soonthornvacharin concluded. Chanda, Soonthornvacharin, and the rest of the team are already planning on further investigating the intricate relationship between RIG-I and KHSRP.

Chanda’s study was recently published in the journal Nature Microbiology.

Source: Sanford Burnham Prebys Medical Discovery Institute

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 23, 2019
Immunology
AUG 23, 2019
Making Opioids Safer
The opioid crisis results in 130 American deaths every day, and both prescribed and synthetic opioids are at the core of the epidemic.  Any other drug...
AUG 31, 2019
Immunology
AUG 31, 2019
AI Not Ready To Predict Acute Kidney Injury
An international group of scientists from the U.S. and U.K. published new research in Nature about the effectiveness of AI in predicting Acute Kidney Injur...
OCT 12, 2019
Immunology
OCT 12, 2019
Treating Alzheimer's? Target Microglia
The body’s own immune cells may be the common denominator in Alzheimer’s disease. In a new study of the relationship between microglia, tau pro...
OCT 14, 2019
Immunology
OCT 14, 2019
This is How Your Immune System Responds to Ebola Vaccination
Vaccines to prevent Ebola are still in their infancy, with experimental-only versions being used only in the most dire of instances. In a new study, scient...
OCT 25, 2019
Drug Discovery & Development
OCT 25, 2019
Novel Therapeutic For Eradicating The Flu Virus
Public Health officials have long warned about pandemic pathogens flying fast around the world. One virus already spreads across the globe annually leading...
NOV 28, 2019
Drug Discovery & Development
NOV 28, 2019
Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer
By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have foun...
Loading Comments...